Teopek Extended-Release Tablets, 300 mg, No. 50 (10 x 5)

In stock: 1
$57.00

Ingredients

Active ingredient: theophylline;

1 tablet contains 300 mg of theophylline (calculated as 100% dry weight);

Excipients: composite polymer carrier (interpolymer complex of polymethacrylic acid and polyethylene glycol), calcium stearate.

Dosage Form

Extended-release tablets.

Main physical and chemical properties: round, white tablets with a flat surface, beveled edges, and a score line. Slight yellowish discoloration is permissible.

Pharmacotherapeutic group

Agents for systemic use in obstructive airway diseases. Xanthines. Theophylline. ATC code R03D A04.

Pharmacological Properties

Pharmacodynamics.

The mechanism of action of theophylline involves non-selective inhibition of phosphodiesterase. Inhibition of type III phosphodiesterase leads to an increase in cAMP concentration in the myofibrils of the large and medium-sized bronchi and bronchioles, intracellular redistribution of calcium ions, accompanied by a decrease in their concentration in the cytosol. Inhibition of type IV phosphodiesterase leads to suppression of the function of mast cells, eosinophils, and T-lymphocytes.

At therapeutic concentrations, theophylline blocks the adenosine-mediated bronchoconstrictor A1 receptors and, to a lesser extent, the bronchodilator A2 receptors. Theophylline reduces the A1/A2 ratio and is an effective antagonist of adenosine receptors at concentrations 20–100 times lower than those required to inhibit phosphodiesterase.

Its stimulating effect on the respiratory center leads to increased pulmonary ventilation by enhancing the contractile capacity of the intercostal muscles and the diaphragm.

By dilating the pulmonary vessels, theophylline reduces pressure in the pulmonary circulation (reducing transient pulmonary hypertension during a bronchial asthma attack) and and improves the pumping function of the right and left ventricles of the heart.

Theophylline increases the synthesis and secretion of endogenous catecholamines and exerts a diuretic effect by increasing renal blood flow and glomerular filtration. It has a stimulating effect on the central nervous system.

Pharmacokinetics.

Theopek has a prolonged effect. When administered twice daily, therapeutic blood concentrations are maintained throughout the day. The therapeutic concentration in blood serum is 10–20 μg/mL (55–110 μmol/L).

The bioavailability of theophylline is approximately 90%. It crosses the blood-brain barrier. The time to reach peak blood concentration is 3–6 hours. The half-life (T½) of theophylline is 6–12 hours in nonsmokers and 4–5 hours in smokers. It is metabolized in the liver by cytochrome P450 isoenzymes to 1,3-dimethyluric acid, 1-methyluric acid,

and 3-methylxanthine. Metabolites are excreted primarily in the urine. The clearance of theophylline is reduced in elderly patients, patients with impaired liver function, and patients with heart failure. In smokers, the clearance of theophylline is increased.

Indications

  • Bronchial asthma;
  • chronic obstructive pulmonary disease (chronic obstructive bronchitis, pulmonary emphysema);
  • pulmonary hypertension;
  • central sleep apnea syndrome.

Contraindications

  • Hypersensitivity to theophylline, other xanthines (e.g., caffeine, pentoxifylline, theobromine), or any other components of the drug;
  • epilepsy;
  • glaucoma;
  • acute myocardial infarction, severe hypertension, acute cardiac arrhythmias;
  • active gastric and duodenal ulcers;
  • hyperthyroidism;
  • severe liver dysfunction;
  • use in children concurrently with ephedrine;
  • porphyria.

Interactions with Other Medications and Other Types of Interactions

Drugs that increase the clearance of theophylline: aminoglutamide, antiepileptic drugs (e.g., phenytoin, carbamazepine, primidone), isoproterenol, magnesium hydroxide, moracizin, rifampicin, ritonavir, sulfinpyrazone, barbiturates (especially phenobarbital and pentobarbital). In patients taking one or more of the above-mentioned drugs concomitantly with theophylline, serum theophylline concentrations should be monitored and the dose increased if necessary.

Drugs that reduce the clearance of theophylline: allopurinol, acyclovir, carbimazole, phenylbutazone, imipenem, calcium channel blockers, cimetidine, fluconazole, furosemide, pentoxifylline, disulfiram, interferon, nizatidine, calcium antagonists (verapamil, diltiazem), amiodarone, acetaminophen, probenecid, ranitidine, tacrine, propafenone, propranolol, oxpentifylline, isoniazid, lincomycin, methotrexate, zafirlukast, mexiletine, fluoroquinolones (ofloxacin, norfloxacin, when using ciprofloxacin, the dose must be reduced by at least 60%; for enoxacin, by 30%), macrolides (clarithromycin, erythromycin), ticlopidine, tiabendazole, viloxazine hydrochloride, oral contraceptives, the influenza vaccine, as well as herbal preparations containing St. John’s wort (Hypericum perforatum). Patients taking one or more of the above-mentioned drugs concurrently with theophylline should have their serum theophylline levels monitored and the dose reduced if necessary.

Combinations of theophylline with benzodiazepines, halothane, and lomustine should be used with particular caution. Anesthesia with halothane may cause serious cardiac arrhythmias in patients taking theophylline.

The simultaneous use of Teopek with large amounts of food and beverages containing methylxanthines (coffee, tea, cocoa, chocolate, Coca-Cola, and similar stimulant beverages) should be avoided, medications containing xanthine derivatives (caffeine, theobromine, pentoxifylline), α- and β-adrenergic agonists (selective and nonselective) and glucagon, due to the potentiation of theophylline’s effects.

Concomitant use of theophylline with β-adrenergic blockers may antagonize its bronchodilator effect; with ketamine and quinolones—it lowers the seizure threshold; when used with adenosine, carbonate, and β-receptor antagonists, the efficacy of the latter is reduced; and when used with doxapram, it may cause central nervous system stimulation.

Theophylline may enhance the effects of diuretics and reserpine; it may reduce the effectiveness of adenosine, lithium carbonate, and β-receptor antagonists.

There is conflicting evidence regarding the potentiation of theophylline’s effects in influenza-like illnesses.

Xanthines may potentiate hypokalemia caused by therapy with β2-agonists, steroids, diuretics, and hypoxia. This is particularly relevant for hospitalized patients with severe asthma who require monitoring of serum potassium levels.

The combination of theophylline and fluvoxamine should be avoided. If this combination cannot be avoided, patients should be prescribed half the dose of theophylline, and plasma concentrations of theophylline should be monitored.

Special Considerations for Use

Theopek should be used with caution, and only when absolutely necessary, in cases of unstable angina, heart diseases in which tachyarrhythmia may occur, hypertrophic obstructive cardiomyopathy, impaired renal or hepatic function, patients with a history of peptic ulcer disease, and patients aged 60 years or older.

The use of theophylline in cases of severe atherosclerosis or sepsis is possible with caution, under medical supervision, provided there are indications for its use. Restrictions on the use of theophylline in gastroesophageal reflux are related to its effect on the smooth muscles of the cardioesophageal sphincter, which may worsen the patient’s condition in cases of gastroesophageal reflux, thereby increasing reflux.

Close monitoring is required when treating patients with cardiac arrhythmias, hypertension, other cardiovascular diseases, or acute febrile conditions with theophylline.

During treatment with theophylline, close monitoring is required, and the dose should be reduced when treating patients with heart failure, chronic alcoholism, liver dysfunction (especially in cirrhosis), reduced blood oxygen levels (hypoxemia), elevated body temperature, or those with pneumonia or viral infections (especially influenza) due to a possible reduction in theophylline clearance. At the same time, theophylline levels in blood plasma must be monitored.

Patients with a history of seizures should avoid theophylline and use alternative treatments.

Special caution is required when administering the drug to patients suffering from insomnia, as well as to elderly men with a history of benign prostatic hyperplasia, due to the risk of urinary retention.

If it becomes necessary to administer aminophylline (theophylline-ethylenediamine) to patients who have previously taken Teopek, plasma theophylline levels must continue to be monitored.

Given that bioequivalence cannot be guaranteed between individual extended-release theophylline-containing medications, switching from treatment with Teopek, extended-release tablets, to another extended-release xanthine preparation must be carried out through repeated dose titration and following clinical evaluation.

Smoking and alcohol consumption may lead to increased theophylline clearance and, consequently, to a reduction in its therapeutic effect and the need for higher doses.

Theophylline may alter certain laboratory parameters: it may increase the amount of fatty acids and the level of catecholamines in the urine.

If the recommended dose is ineffective or if side effects occur, the plasma concentration of theophylline should be determined.

Fever reduces the clearance of theophylline. In cases of acute fever, it may be necessary to reduce the dose of the drug to avoid toxicity.

Theophylline is not the drug of choice for children with bronchial asthma.

Use During Pregnancy or Breastfeeding

Theophylline crosses the placenta and passes into breast milk. The use of Teopek during pregnancy is permissible only if the expected benefit to the mother outweighs the potential risk to the fetus. In pregnant women, serum theophylline concentrations should be monitored more frequently, and the dose should be adjusted accordingly. The use of theophylline should be avoided late in pregnancy, as it may inhibit uterine contractions and cause fetal tachycardia.

If the drug must be used in breastfeeding women, it is recommended to discontinue breastfeeding.

Effect on the ability to drive or operate machinery

Some side effects (e.g., dizziness) may affect the ability to drive or operate machinery. Patients should be advised not to drive or operate hazardous machinery until it is determined that they respond normally to treatment.

Dosage and Administration

Take Teopek orally 30–60 minutes before a meal or 2 hours after a meal, with plenty of liquid. The tablet may be split in half but must not be crushed, chewed, or dissolved in water. In some cases, to reduce irritation of the stomach lining, the medication should be taken during or immediately after a meal.

The dosing regimen should be determined individually, depending on the patient’s age, body weight, and metabolic characteristics.

The initial daily dose for adults and children aged 12 years and older weighing more than 45 kg is 300 mg (1 tablet once daily). After 3 days of treatment, increase the daily dose to 450 mg (1½ tablets); after another 3 days of treatment, if necessary, the daily dose may be increased to 600 mg (1 tablet twice daily). Dose increases are permitted only if the medication is well tolerated.

For children aged 6 to 12 years with a body weight of 20–45 kg, the daily dose is 150 mg (½ tablet once daily). After 3 days of treatment, increase the daily dose to 300 mg (½ tablet twice daily); and after another 3 days of treatment, the daily dose may be increased to 450–600 mg (1½ tablets once daily or 1 tablet twice daily).

Patients with central sleep apnea syndrome may take a single dose of Teopek at night.

Further dose increases are recommended based on the determination of theophylline concentration in serum.

For patients who smoke, the daily dose may be gradually increased to 900–1,050 mg (3–3½ tablets).

Children.

This medication should not be used in children under 6 years of age weighing less than 20 kg.

Overdose

Overdose is observed when the serum theophylline concentration exceeds 110 μmol/L.

Symptoms: Severe symptoms may develop 12 hours after an overdose of extended-release formulations.

Gastrointestinal tract: nausea, vomiting (often severe), epigastric pain, diarrhea, hematemesis, pancreatitis.

Nervous system: delirium, agitation, anxiety, tremor, hyperreflexia of the extremities and convulsions, muscle rigidity. In very severe cases, coma may develop.

Cardiovascular system: sinus tachycardia, ectopic rhythm, supraventricular and ventricular tachycardia, hypertension/hypotension.

Metabolic disorders: metabolic acidosis, hypokalemia, hypophosphatemia, hypercalcemia, hypomagnesemia, hyperglycemia, rhabdomyolysis.

Other: respiratory alkalosis, hyperventilation, acute renal failure, dehydration, or exacerbation of other adverse reactions.

Treatment. Discontinuation of the drug, gastric lavage, oral administration of activated charcoal, osmotic laxatives; hemodialysis. Monitor serum theophylline levels until they return to normal; monitor ECG and renal function. Diazepam is indicated in cases of convulsive syndrome. For patients without bronchial asthma, non-selective beta-blockers may be used if severe tachycardia occurs. In severe cases, the elimination of theophylline can be accelerated by hemosorption or hemodialysis. In cases of hypokalemia, urgent intravenous infusion of potassium chloride solution is required, along with monitoring of potassium and magnesium levels in plasma. In cases of ventricular arrhythmias, the use of antiarrhythmic drugs with anticonvulsant effects, such as lidocaine, should be avoided due to the risk of exacerbating seizures. To control vomiting, antiemetics such as metoclopramide or ondansetron should be used.

In cases of tachycardia with adequate cardiac output, it is preferable not to administer treatment.

Side Effects

Adverse reactions are usually observed at plasma theophylline concentrations > 20 μg/mL.

Immune system: hypersensitivity reactions, including angioedema, anaphylactic reactions, and bronchospasm.

Skin and subcutaneous tissue: skin rashes, exfoliative dermatitis, pruritus, urticaria.

Gastrointestinal tract: heartburn, decreased appetite/anorexia with long-term use, nausea, vomiting, abdominal pain, diarrhea, gastroesophageal reflux, exacerbation of peptic ulcer disease, stimulation of gastric acid secretion.

Cardiovascular system: palpitations, tachycardia, decreased blood pressure, arrhythmias.

Nervous system: dizziness, headache, restlessness, tremor, confusion, delirium, seizures.

Psychiatric disorders: increased excitability, irritability, insomnia, sleep disturbances.

Urinary system: increased diuresis, especially in children; urinary retention in elderly men.

Other: fever, rhabdomyolysis, metabolic acidosis, sensation of heat and facial flushing, increased sweating, weakness, shortness of breath.

Laboratory parameters: During treatment with theophylline, the following may occur: hypokalemia, hypercalcemia, hyperglycemia, hyperuricemia, and disturbances in blood acid-base balance.

Side effects decrease when the dose is reduced.

Shelf life

5 years.

Storage conditions

In the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

10 tablets per blister pack, 5 blister packs per box.

Dispensing Category

By prescription.